Global Innovation Policy Center
GIPC is leading efforts to promote innovation and creativity globally by advocating for strong IP standards.
The U.S. Chamber of Commerce’s Global Innovation Policy Center is working around the world to champion innovation and creativity through intellectual property standards that create jobs, save lives, advance global economic and cultural prosperity, and generate breakthrough solutions to global challenges.
Explore more
Leadership
Latest Content
GLP-1 medicines are revolutionizing obesity treatment and improving patient health. Policymakers must support continued innovation and increase patient access.
Current congressional proposals will impose unnecessary red tape, undermining America’s innovation ecosystem.
U.S. Customs and Border Protection and the Chamber share expertise on the dangers of counterfeit goods and how to keep communities safe from illicit trade.
Shop Smart campaign educates consumers to keep Americans safe.
The CHIPS and Science Act is making substantial investments in America’s semiconductor industry and laying the foundation for additional investments in research and development.
The U.S. Chamber of Commerce (“Chamber”) Global Innovation Policy Center (“GIPC”) appreciates the opportunity to comment on the proposed plan to promote access to taxpayer-funded inventions created through the National Institutes of Health’s (“NIH”) intramural research and development program (“Proposal”).
Creative content has the power to unite global citizens across borders. Creative efforts are enabled by copyright law, which is critical to the protection of creators’ works and their ability to continue to hone their craft and create the next greatest hit.
The U.S. Chamber of Commerce (“Chamber”) Global Innovation Policy Center (“GIPC”) appreciates the opportunity to comment on the U.S. Patent and Trademark Office’s (“USPTO”) proposed changes to the rules on the use of terminal disclaimers.
The U.S. Chamber of Commerce Global Innovation Policy Center urges the Centers for Medicare and Medicaid Services to re-evaluate the approach taken in the Agency's Draft Guidance, which proposes to implement the second year of the Medicare Drug Price Negotiation Program established by the Inflation Reduction Act.
